COR LOE Recommendations I A In adults with elevated blood pressure (BP) or hypertension, including those requiring antihypertensive medications nonpharmacological interventions are recommended to reduce BP. These include: ; a heart-healthy dietary patternS4.4-6 S4.4-8 ; ; dietary potassium supplementationS4.4-14 S4.4-18 ; increased physical activity with a structured exercise programS4.4-3,S4.4-5,S4.4-11, ; and Adapted from recommendations in the 2017 Hypertension Clinical Practice Guidelines.S4.4-1 I SBP:A In adults with an estimated 10-year ASCVD risk* of 10% or higher and an average systolic BP (SBP) of 130 mm Hg or higher or an average diastolic BP (DBP) of 80 mm Hg or higher, use of BP-lowering medications is recommended for primary prevention of Adapted from recommendations in the 2017 Hypertension Clinical Practice Guidelines.S4.4-1 DBP:C-EO I SBP:B-RSR In adults with confirmed hypertension and a 10-year ASCVD event risk of 10% or higher, a BP target of less than 130/80 mm Hg is Adapted from recommendations in the 2017 Hypertension Clinical Practice Guidelines.S4.4-1 DBP:C-EO I SBP:B-RSR In adults with hypertension and chronic kidney disease, treatment to a BP goal of less than 130/80 mm Hg is Adapted from recommendations in the 2017 Hypertension Clinical Practice Guidelines.S4.4-1 DBP:C-EO I SBP:B-RSR In adults with T2DM and hypertension, antihypertensive drug treatment should be initiated at a BP of 130/80 mm Hg or higher, with a treatment goal of less than Adapted from recommendations in the 2017 Hypertension Clinical Practice Guidelines.S4.4-1 DBP:C-EO I C-LD In adults with an estimated 10-year ASCVD risk <10% and an SBP of 140 mm Hg or higher or a DBP of 90 mm Hg or higher, initiation and use of BP-lowering medication Adapted from recommendations in the 2017 Hypertension Clinical Practice Guidelines.S4.4-1 IIb SBP:B-NR In adults with confirmed hypertension without additional markers of increased ASCVD risk, a BP target of less than 130/80 mm Hg may be reasonable.S4.4-59 S4.4-62 Adapted from recommendations in the 2017 Hypertension Clinical Practice Guidelines.S4.4-1 DBP:C-EO *ACC/AHA pooled cohort equations to estimate 10-year risk of ASCVD. 